Bleeding-Control Device Market Set to Hit $4.67bn

Global spending on devices that stop severe bleeding is on track to climb from $3.47 billion in 2025 to $4.67 billion by 2030, according to new market analysis, as hospitals, militaries and emergency responders race to adopt faster and more portable trauma technology. The projected 6.1% compound annual growth rate underscores how bleeding management has moved from a niche surgical concern to a broader priority spanning battlefield medicine, maternal health and disaster preparedness.

What Is Fueling Demand

The forecast growth stems from several converging pressures rather than a single catalyst. Rising trauma and accident rates, expanding emergency medical services, and standardized bleeding-control protocols have already pushed the market up 6.4% between 2025 and 2026 alone.

Military procurement is also a significant factor, with defense agencies seeking lighter, field-deployable hemostatic dressings and tourniquets that can be applied by non-specialists in combat conditions. That overlaps with civilian emergency preparedness programs, which have increasingly trained first responders and even bystanders in bleeding-control techniques following mass-casualty incidents.

Surgical demand adds a further layer of growth, as more complex procedures across cardiovascular, orthopedic and neurosurgical specialties require advanced sealants and clamps to manage intraoperative blood loss. The market's product mix — spanning gauze and hydrogel dressings to thrombin-based hemostats and pneumatic tourniquets — reflects how differentiated the clinical need has become.

Maternal Health Emerges as a Growth Front

One of the more notable shifts highlighted in the data is the growing focus on postpartum hemorrhage, a leading cause of maternal mortality worldwide. Devices designed specifically for this use aim to halt bleeding after childbirth by promoting clotting or constricting blood vessels, offering an option when conservative treatments are insufficient.

Organon Canada's September 2024 launch of the JADA System, which uses low-level vacuum technology to stimulate uterine contractions, illustrates how manufacturers are targeting this underserved segment. It also signals that hemorrhage control innovation is expanding beyond trauma bays and operating rooms into obstetric wards, a shift with implications for how emergency medical infrastructure is built out in both developed and developing health systems — a trend echoed in efforts to extend care through platforms like the mobile hospital platform for rural healthcare being developed elsewhere in the sector.

A 2025 collaboration between the American College of Surgeons and Lifesaving Technologies, focused on improving access to hemorrhage control products and strengthening clinician training, points to a parallel trend: manufacturers are pairing product development with education initiatives rather than relying on device sales alone. That approach may prove decisive in a market where a wide roster of established and emerging suppliers — including Medtronic, Stryker, Becton Dickinson, Baxter International, Teleflex and smaller specialists such as Z-Medica and Tricol Biomedical — compete for share across dressings, hemostatic agents, clamps and surgical sealants.

With market size expected to grow by roughly $1 billion between 2025 and 2030, the hemorrhage control sector appears set for steady rather than explosive expansion. Analysis from The Business Research Company suggests the next phase of growth will hinge less on entirely new chemistry and more on getting existing hemostatic innovations into the hands of first responders, surgeons and maternity units faster.